T-cell-based diagnosis of tuberculosis infection in children in Lithuania: a country of high incidence despite a high coverage with bacille Calmette-Guerin vaccination.
BACKGROUND
Lithuania is a country with a high incidence of tuberculosis (TB), despite a high coverage with bacille Calmette-Guerin (BCG) vaccination. Until now the only method used to detect latent TB infection was the tuberculin skin test (TST). However, TST may have a cross reactivity to the BCG vaccine and to environmental mycobacteria. The aim of this study was to conduct assessments of the diagnostic accuracy of the T-cell based test (T SPOT TB) for TB in children who had previously been BCG vaccinated and compare these with the results of the TST.


METHODS
Between January 2005 and February 2007, children with bacteriologically confirmed TB, children having contacts with a case of infectious pulmonary TB and children without any known risk for TB were tested with both the TST and T SPOT TB.


RESULTS
The TST and T SPOT TB tests were positive for all patients in the "culture-confirmed TB" group. Whereas, in the "high risk for TB" group, the TST was positive for 60%, but the T SPOT TB test, only for 17.8%. Meanwhile the results for the "low risk for TB" group were 65.4% and 9.6%, respectively. A correlation between the TST and T SPOT TB was obtained in the "culture-confirmed TB" group where the TST > or =15 mm (r = 0.35, p < 0.001).


CONCLUSIONS
The T-cell based method is more objective than the TST for identifying latent TB infection in children who had been previously BCG vaccinated. This method could be useful in countries like Lithuania where there is a high incidence of TB despite a high coverage with BCG vaccination. It may also help to avoid unnecessary chemoprophylaxis when TST reactions are false-positive.
Hansted
Edita
E
Department of Pediatric Diseases, Kaunas University of Medicine, Eiveniu 2, 50009 Kaunas, Lithuania. edita.hansted@gmail.com
Andriuskeviciene
Angele
A
Sakalauskas
Raimundas
R
Kevalas
Rimantas
R
Sitkauskiene
Brigita
B
D000293:Adolescent; D001500:BCG Vaccine / Q000627:therapeutic use*; D002648:Child; D005189:False Positive Reactions; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D015994:Incidence; D007371:Interferon-gamma / Q000097:blood; D008097:Lithuania / Q000453:epidemiology; D008297:Male; D012189:Retrospective Studies; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology*; D014374:Tuberculin Test; D014376:Tuberculosis / Q000453:epidemiology* / Q000473:pathology / Q000517:prevention & control*
D001500:BCG Vaccine; D007371:Interferon-gamma
JAMA. 2005 Jun 8;293(22):2756-61
15941805
Am J Respir Crit Care Med. 2001 Mar;163(4):824-8
11282752
Medicina (Kaunas). 2007;43(7):519-22
17768365
Clin Microbiol Infect. 2007 Aug;13(8):836-8
17501976
Pediatrics. 2009 Jan;123(1):30-7
19117857
Clin Infect Dis. 2005 Jan 15;40(2):211-7
15655737
Eur Respir J. 2007 Oct;30(4):722-8
17537773
Emerg Infect Dis. 2007 Apr;13(4):553-8
17553269
Clin Med Res. 2006 Dec;4(4):266-72
17210976
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47
10764341
Am J Respir Crit Care Med. 2006 Oct 1;174(7):736-42
16799073
J Infect. 2007 Mar;54(3):e169-74
17188363
Lancet. 2006 Apr 22;367(9519):1328-34
16631911
Clin Infect Dis. 2007 Aug 1;45(3):322-8
17599309
Eur Respir J. 2006 Jul;28(1):24-30
16611658
Int J Tuberc Lung Dis. 2005 Nov;9(11):1242-7
16333932
Lancet Infect Dis. 2008 Jun;8(6):359-68
18450516
Pediatrics. 2007 Jan;119(1):e1-5
17200234
Am J Respir Crit Care Med. 2007 Mar 15;175(6):618-27
17170386
Int J Tuberc Lung Dis. 2006 Dec;10(12):1342-6
17167950
Ann Rheum Dis. 2004 Nov;63 Suppl 2:ii50-ii56
15479872
Lancet. 2001 Jun 23;357(9273):2017-21
11438135
Am J Respir Crit Care Med. 2007 Feb 1;175(3):282-7
17082492
Ann Intern Med. 2007 Mar 6;146(5):340-54
17339619
Int J Tuberc Lung Dis. 2005 Feb;9(2):170-4
15732736
Clin Infect Dis. 2004 Mar 1;38(5):754-6
14986262
Medicina (Kaunas). 2003;39(1):30-5
12576763
Eur J Clin Microbiol Infect Dis. 2005 Aug;24(8):529-36
16133410
Clin Vaccine Immunol. 2007 Sep;14(9):1239-41
17626157